Brazilian biotechnology startup BioLinker has successfully raised $1.7 million in a new funding round as the company prepares to scale its synthetic biology operations and expand its footprint into the Amazon region. The latest financial injection is anchored by Axcell, a prominent investment firm that contributed $1.4 million to the round. Additional financial backing came from the São Paulo Research Foundation, known as FAPESP, which provided approximately $240,000 through its competitive PIPE Phase 2 program, designed to support innovative research and development in small businesses.
Founded in 2018 by a team of visionary scientists hailing from the University of São Paulo, BioLinker specializes in the development and manufacturing of recombinant proteins. Leveraging cutting-edge synthetic biology and advanced genetic engineering techniques, the company creates specialized products that serve critical functions across multiple sectors, including scientific research, medical and clinical diagnostics, and various industrial applications. The startup’s core mission has centered on streamlining the production of complex biological components, positioning itself as a reliable partner for organizations that require high-purity proteins for rigorous applications.
With the fresh capital secured from Axcell and FAPESP, BioLinker is setting its sights on a major infrastructural expansion. The company plans to utilize a significant portion of the funds to construct a state-of-the-art automated laboratory located at the Amazon BioBusiness Center in Manaus. This strategic move places the biotech venture in a unique position to leverage the rich biodiversity of the region while contributing to the technological development of Northern Brazil. The new facility will not be a traditional wet lab; instead, it is designed to incorporate advanced robotics capable of generating vast amounts of biological data at scale.
The integration of robotics and high-throughput data generation is a crucial component of BioLinker’s broader strategy. The biological data harvested at the Manaus facility will be directly applied to training sophisticated artificial intelligence models. By combining synthetic biology with machine learning, the startup aims to optimize protein design and accelerate DNA production capabilities throughout Brazil. This technological convergence is expected to significantly reduce production bottlenecks and open up new avenues for research and commercialization within the Latin American biotech landscape.
In tandem with its physical and technological expansion, BioLinker is preparing for a substantial workforce growth. The company currently operates with a lean team of 12 dedicated professionals. Thanks to the new funding round, leadership plans to double its headcount, bringing the total number of employees to 24. This workforce expansion will encompass a range of specialized roles, including biotechnology researchers, data scientists, automation engineers, and operational staff required to run the new Manaus laboratory efficiently.
Despite the successful closure of this latest capital injection, BioLinker’s funding round remains actively open. Company leadership is currently engaged in strategic discussions with international investors, actively seeking a global partner to provide additional financial support and strategic guidance. This ongoing fundraising effort is designed to pave the way for a much larger Series A funding round, which the startup anticipates launching within the next two years as it accelerates its international market penetration and scales its technological infrastructure.
Financially, BioLinker stands on solid ground as it enters this new phase of growth. The company already generates steady, recurring revenue through its existing portfolio of recombinant protein products and services. Management projects that the newly secured $1.7 million capital injection will provide more than enough runway to comfortably fund three years of continuous operations, research and development, and facility construction without placing immediate pressure on cash flow. As BioLinker continues to bridge the gap between synthetic biology, artificial intelligence, and regional development in the Amazon, the startup remains focused on executing its long-term vision of transforming the biotechnology sector in Brazil and beyond.
